A grape seed procyanidin extract inhibits HDAC activity leading to increased Pparα phosphorylation and target-gene expression

Laura E. Downing, Bradley S. Ferguson, Kelvin Rodriguez and Marie-Louise Ricketts

Department of Agriculture, Nutrition and Veterinary Sciences, University of Nevada Reno, Reno, NV, USA

Scope: Histone deacetylases (HDACs) have emerged as epigenetic regulators of risk factors associated with the metabolic syndrome (MetS), and certain botanical extracts have proven to be potent HDAC inhibitors. Understanding the role of dietary procyanidins in HDAC inhibition is important in exploring the therapeutic potential of natural products.

Methods: C57BL/6 mice were gavaged with vehicle (water) or grape seed procyanidin extract (GSPE, 250 mg/kg) and terminated 14 h later. Liver and serum were harvested to assess the effect of GSPE on HDAC activity, histone acetylation, Pparα activity and target-gene expression, and serum lipid levels.

Results: GSPE increased histone acetylation and decreased Class I HDAC activity in vivo, and dose-dependently inhibited recombinant HDAC2 and 3 activities in vitro. Accordingly, Pparα gene and phosphorylated protein expression were increased, as were target genes involved in fatty acid catabolism, suggesting increased Pparα activity. Serum fibroblast growth factor 21 (Fgf21) was elevated, and triglyceride levels were reduced by 28%.

Conclusion: GSPE regulates HDAC and Pparα activities to modulate lipid catabolism and reduce serum triglycerides in vivo.

Keywords: Fgf21 / HDAC / Pparα / Procyanidins / Triglycerides

Additional supporting information may be found in the online version of this article at the publisher’s web-site

1 Introduction

The metabolic syndrome (MetS), a cluster of biochemical and physiological abnormalities, including central adiposity, hypertension, hyperglycemia, hypertriglyceridemia, and low HDL levels [1], is associated with the development of cardiovascular disease and other health issues, and currently affects approximately one in three adults in the United States with increasing prevalence worldwide [2]. Epigenetics, heritable alterations in gene expression arising from environmental and other external influences, may play a role in the development of MetS [3]. Epigenetic changes are governed in large part by histone deacetylases (HDACs), which remove acetyl groups from histones as part of a corepressor complex that compact chromatin and effectively inhibits the transcription of certain genes [3]. Because HDACs play a key role in repressing gene expression, HDAC inhibitors may exert therapeutic effects on diseases associated with metabolic dysregulation and MetS [3–5].

Class I HDACs (HDACs1, 2, and 3) are targets of many HDAC inhibitors [5]. HDAC2 and 3 have demonstrated important roles in lipid metabolism via regulation of nuclear receptor expression and activity [4, 6–8]. In particular, HDAC3 inhibition via butyrate, trichostatin A, or gene knockdown in mice upregulated the activity of peroxisome proliferator-activated receptor alpha (Pparα), a primary regulator of hepatic lipid metabolism, and also increased the expression of downstream Pparα target genes involved in fatty acid catabolism, including fibroblast growth factor 21 (Fgf21) [4]. This suggests that HDAC inhibition may be a potential avenue through which disorders in lipid metabolism can be treated.

Studies with botanical extracts suggest that certain plant flavonoids may act as HDAC inhibitors [9–11]. Grape seed procyanidin extracts, in particular, have been shown to inhibit HDAC activity [12]. The present study investigated the effect of grape seed procyanidin extract on HDAC activity and lipid metabolism in vivo.
procyanidins were shown to significantly decrease HDAC activity and increase levels of acetylated H3K9 and H3K14, leading to increased gene expression, in vitro in skin cancer cells [12]. Grape seed procyanidin extract (GSPE) is primarily composed of monomeric and dimeric procyanidins and exerts numerous beneficial effects on MetS risk factors [13–18]. We previously showed that GSPE lowers serum triglycerides by 50% in vivo, an important risk factor for MetS, which was accompanied by increased fatty acid catabolism gene expression [16]. However, the ability of GSPE to act as an HDAC inhibitor as an underlying mechanism to decrease triglyceride levels remains unexplored.

This study was designed to test the hypothesis that GSPE inhibits HDAC activity, leading to increased PPARα target gene expression and therefore fatty acid catabolism as a mechanism to lower serum triglycerides. Identifying mechanisms by which GSPE lowers serum triglyceride levels could facilitate utilization in the treatment of MetS risk factors, including hypertriglyceridemia.

Herein, we show that GSPE treatment in C57BL/6 mice repressed HDAC activity, increased PPARα phosphorylation, activated Ppara target genes involved in hepatic fatty acid catabolism, and increased serum Fgf21 levels, all of which were accompanied by a 28% decrease in serum triglyceride levels. Our results suggest that HDAC inhibition may be a novel mechanism leading to changes in lipid metabolism following GSPE administration.

## 2 Materials and methods

### 2.1 Chemicals and antibodies

All chemicals and antibodies were obtained from Thermo Fisher Scientific, unless otherwise stated. GSPE was obtained from Les Dérivés Réiniques et Terpéniques (Dax, France) [16, 17, 19], and was analyzed in-house, as described in the Supporting Information. GSPE has a total polyphenol content > 68%. Results of the analysis are presented in the Supporting Information Fig. 1 and Supporting Information Table 1. Antibodies for HDAC1, HDAC2, HDAC3, acetyl-lysine, acetyl-α-tubulin, acetyl-H3K9, and histone H3 were obtained from Cell Signaling, while those for β-actin and α-tubulin were purchased from Sigma–Aldrich and Santa Cruz Biotech, respectively.

### 2.2 Animal studies

All procedures were approved by the Institutional Animal Care and Use Committee at the University of Nevada, Reno, NV, USA (Protocol #: 00502). Four-week-old, male C57BL/6 mice (n = 4 per group) were purchased from Charles River Laboratories (Wilmington, MA, USA), housed under standard conditions and provided standard rodent chow (Harlan Teklad 8664) and water ad libitum. At 8 wks of age the mice were orally gavaged with either vehicle (water) or GSPE (250 mg/kg) at 9 p.m. and again at 9 a.m. the next day and terminated at 11 a.m. after a 2 h fast [16, 17, 20, 21]. Blood was collected via retro-orbital bleeding under isoflurane anesthesia and livers were snap frozen in liquid nitrogen and stored at −80°C. The GSPE dose utilized is one-fifth of the no-observed-adverse-effect level, as previously described for GSPE in rats [22], and effectively lowers serum triglyceride levels and modulates gene expression [16, 17, 20, 21]. Based on metabolic comparison, the dose of GSPE utilized in this study is equivalent to ~703 mg procyanidins/day in a 60 kg human [23].

### 2.3 RNA isolation and gene expression

RNA was extracted from frozen liver using TRIzol (Life Technologies) according to the manufacturer’s instructions. Complementary DNA was synthesized using supercript III reverse transcriptase (Life Technologies). Gene expression was assessed by real-time quantitative PCR using a CFX96 Real-Time System (Bio-Rad). Fold change in gene expression was calculated using the ΔΔCt method, and expression of β-actin and Gapdh were used as endogenous controls. Primer sequences are available in Supporting Information Tables 2 and 3.

### 2.4 HDAC activity assays and Western blot analysis

Frozen mouse liver (untreated control) was homogenized in lysis buffer (300 mM sodium chloride and 0.5% Triton-X 100 in phosphate buffered saline) with Halt protease and phosphatase inhibitor cocktail. Protein concentration was assessed using a Pierce BCA protein assay kit. HDAC activity was assessed as previously reported [24, 25], and is detailed in the Supporting Information. The protein lysate was also used for Western analysis, as detailed in the Supporting Information.

### 2.5 Serum parameter analyses

Serum triglyceride and total cholesterol levels were determined using commercially available kits. Serum Fgf21 levels were determined using an ELISA kit (R&D Systems) according to the manufacturer’s instructions.

### 2.6 Statistical analyses

One-way analysis of variance followed by Tukey’s post hoc test (in vitro analyses) or a Student’s t-test (in vivo analyses) was used to detect statistical significance (GraphPad Prism version 6.05 for Windows). Value of p < 0.05 was considered significant. Results are expressed as mean ± SEM, n = 4, analyzed in triplicate.
3 Results and discussion

3.1 GSPE inhibits HDAC activity and increases histone acetylation

In vitro HDAC activity analyses using mouse liver cell lysate showed that increasing concentrations of GSPE inhibited the activities of Class I, IIa, and IIb HDACs (Fig. 1). Further in vivo studies showed that, while there were no changes in Class I HDAC protein expression (Fig. 2A), Class I HDAC activity was significantly repressed (Fig. 2C). It is important to note that inhibition of HDACs can occur not only through changes in protein levels of the enzyme, but also via changes in activity [9]. Increased histone acetylation, evidenced by elevated protein expression of acetyl-H3K9 and acetyl-lysine in GSPE-treated mouse liver, also indicates decreased HDAC activity (Fig. 2A and B) [26]. In contrast to the in vitro assays, Class IIa and IIb activities were not significantly inhibited in vivo (Fig. 2C).

3.2 GSPE inhibits recombinant HDAC2 and 3 activities

Since GSPE repressed Class I HDAC activity in vivo, we next assessed the effect on recombinant HDAC1, 2, and 3 activities. GSPE strongly and dose-dependently repressed HDAC2 activity at all concentrations (Fig. 3B) and inhibited HDAC3 activity dose-dependently at 30 and 100 mg/L (Fig. 3C). HDAC2 and 3 exert regulatory control on hepatic lipid metabolism, partly due to modulating nuclear receptor expression [4, 6–8], particularly Ppara, the master regulator of hepatic lipid metabolism [4]. Li et al. [4] demonstrated that HDAC3 inhibition in mice upregulated Ppara activity, and phosphorylation of Ppara is required for its transcriptional activity [27, 28]. Based on these facts, our results suggest that inhibition of HDAC3 by GSPE facilitated increased phosphorylation (Fig. 4) and, therefore, Ppara transactivity [27], although further research is needed to determine the underlying mechanism. While GSPE strongly suppressed HDAC2 activity (Fig. 3B), additional studies are necessary to determine whether HDAC2 inhibition leads to changes in Ppara expression and activity.

The observation that GSPE increases recombinant HDAC1 activity (Fig. 3A) strongly suggests that GSPE is not a global HDAC inhibitor but instead may specifically target HDAC2 and 3. GSPE increases hepatic expression of small heterodimer partner (Shp) in a farnesoid x receptor (Fxr)-dependent manner, which leads to repression of sterol regulatory element binding protein (Srebp1c), the master regulator of lipogenesis, as a mechanism to lower serum triglyceride levels [16, 17]. Shp exerts most of its intrinsic inhibitory action via recruitment of HDACs, and the core repressive domains within Shp strongly interact with HDAC1 [29]. Therefore, it may be speculated that an increase in HDAC1 activity could be linked to downstream repressive effects consequential to Shp induction.

3.3 GSPE treatment enhanced Ppara transactivity and target-gene expression in vivo

HDAC3 regulates the function of Ppara, the primary regulator of hepatic fatty acid β-oxidation [4]. Mechanistically, this occurs via inhibition of HDAC3 activity at a PPARα target-gene promoter to enhance transcriptional activity [4]. For example, HDAC3 was shown to be a component of the corepressor complex and to interact with PPARα at the PPRE in the Fgf21 promoter [4]. Additionally, GSPE upregulates genes involved in fatty acid catabolism, namely, carnitine palmitoyltransferase 1a (Cpt1a) [16]. In the present study, we found that GSPE increased the expression of both Ppara (Fig. 4A) and its key target genes involved in all the stages of fatty acid catabolism, including Cpt1a (Fig. 4A). Although Ppara protein expression was decreased (Fig. 4B), phosphorylated Ppara protein expression was increased (Fig. 4C), therefore suggesting increased Ppara transactivity at the promoter regions of direct target genes [27].

Phosphorylation of Ppara can lead to increased transcriptional activity, either in the presence or absence of a ligand.
Figure 2. GSPE increases histone acetylation and blocks Class I HDAC activity in vivo. (A) Global profile of protein acetylation and HDAC1, 2, and 3 expressions in the mouse liver treated with GSPE (250 mg/kg) or vehicle (water). (B) Relative protein expression of acetylated (Ac)-H3K9, Ac-Lys, and Ac-Tub. (C) Class I, Ila, and Iib HDAC activities following GSPE treatment. *p < 0.05.

[30]. However, in the present study, it would be difficult to discern whether the GSPE-induced increase in fatty acid catabolism, which could elevate the level of endogenous ligands, contributed to increased Pparα transactivity, or if phosphorylation of Pparα alone increases transcriptional activity, in a ligand-independent manner [30]. While a ligand-independent activation seems unlikely, due to the presence of fatty acids within the cell, further studies are needed to determine whether GSPE treatment leads to ligand-independent or ligand-dependent transcriptional Pparα activation.

3.4 GSPE treatment induced Fgf21 gene expression and serum levels in vivo

As mentioned above, Fgf21 is induced by HDAC3 inhibition, due to increased Pparα activity at its promoter [4].
Herein, we observed an eightfold increase in Fgf21 gene expression (Fig. 4A) and a concomitant sevenfold increase in serum Fgf21 levels (Table 1). Fgf21 is synthesized exclusively within the liver, and then secreted into the serum to exert diverse physiological effects, possibly via hormonal activity [31], and has demonstrated therapeutic effects on nonalcoholic fatty liver disease, atherosclerosis, and obesity [32]. Furthermore, Fgf21 administration in mice reduces plasma triglyceride levels [33] and recent clinical trials have shown that FGF21 agonism reduces serum triglyceride levels in humans [32]. Our results suggest that GSPE is a powerful inducer of Fgf21 and may indirectly increase Fgf21 gene and protein expression via HDAC inhibition and subsequent Ppara activation.
Table 1. Serum parameters following GSPE administration

<table>
<thead>
<tr>
<th>Serum parameter</th>
<th>VEH</th>
<th>GSPE (250 mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TG (mg/dL)</td>
<td>62.60 ± 1.65</td>
<td>45.29 ± 1.24b2</td>
</tr>
<tr>
<td>CHOL (mg/dL)</td>
<td>107.88 ± 10.25</td>
<td>100.96 ± 6.37</td>
</tr>
<tr>
<td>NEFA (mmol/L)</td>
<td>1.039 ± 0.18</td>
<td>1.103 ± 0.034</td>
</tr>
<tr>
<td>Fgfl (pg/mL)</td>
<td>177.30 ± 17.88</td>
<td>1212.67 ± 328.42a1</td>
</tr>
</tbody>
</table>

CHOL, cholesterol; NEFA, nonesterified fatty acids; TG, triglyceride; VEH, vehicle (water).

a) \( p < 0.05 \)

b) \( p < 0.001 \)

3.5 GSPE treatment upregulated hepatic Fxr and Apoa5 gene expression and reduced serum triglyceride levels in vivo

In addition to the activation of genes involved in hepatic lipid catabolism, hepatic apolipoprotein a5 (Apoa5) and Fxr gene expression were increased (Fig. 4C), effects that correlate with increased triglyceride catabolism [34, 35] and decreased serum triglyceride levels. While Apoa5 is a direct target of PPARα in humans, there is evidence that Fxr regulates Apoa5 in mice [37]. Our results suggest that GSPE upregulates Fxr expression, which in turn activates Apoa5 to allow increased triglyceride catabolism, in agreement with the fact that GSPE induces Apoa5 expression in wild-type but not Fxr−/− mice [17].

Consistent with the observed upregulation in Ppara gene expression and its associated targets involved in lipid catabolism, as well as Fxr and Apoa5, a 28% decrease in serum triglyceride levels was observed in GSPE-treated mice, compared to control (Table 1). Despite the hypocholesterolemic effects seen following GSPE treatment in previous studies [20], no significant change in total serum cholesterol was observed in the present study (Table 1). GSPE inhibits intestinal bile acid (BA) absorption via Fxr-dependent downregulation of BA transporters, thereby reducing enterohepatic recirculation [20]. Decreased BA recirculation leads to increased hepatic BA biosynthesis, initially depleting the cholesterol pool within the liver. Subsequently, TG catabolism is induced to facilitate endogenous cholesterol synthesis from acetyl CoA [20]. The diet used in the present study contained 60 μg/g cholesterol; therefore, dietary-derived cholesterol could first be used for BA biosynthesis, resulting in less of an effect on serum cholesterol levels compared to a previous study [20]. In addition, no changes in serum nonesterified fatty acid levels were observed (Table 1). Nonesterified fatty acid produced from TG catabolism could be used for endogenous cholesterol biosynthesis, rather than being released into the serum, therefore, no significant differences were seen. These results represent the effects following an acute dose of GSPE, which are rapid and potentially short-lived. Future studies should include assessment regarding the effects of repeated GSPE consumption on HDAC inhibition and pharmacokinetics in human subjects over a longer period of time.

4 Concluding remarks

In summary, this particular GSPE inhibits HDAC activity and increases histone acetylation, which correlates with increased Ppara activity and target-gene expression, increased lipid catabolism, and reduced serum triglyceride levels in vivo. Furthermore, we identify GSPE as a potent dietary inducer of Fgf21, an important regulator of lipid metabolism. These results indicate that GSPE warrants further study as an HDAC inhibitor and a potential therapeutic for risk factors associated with MetS, particularly hypertriglyceridemia.

M-LR conceived and designed the studies; LED, BSF, KR, and M-LR performed the studies and analyzed the data; and LED and M-LR wrote the manuscript. Funding was provided by the USDA NIFA (Hatch-NEV0738 and Multistate project W-3122: Beneficial and Adverse Effects of Natural Chemicals on Human Health and Food Safety; and Hatch-NEV0749) to M-LR. Research was also supported by the NIGMS, NIH Grant Number: P20 GM103650. This work is dedicated to the memory of Catherine Ricketts.

The authors have declared no conflict of interest.

5 References


